“I Bet My Life On It”—My Experience as a Patient Representative on an FDA Advisory Panel
In January, Randy Hillard was part of the U.S. Food and Drug Administration committee that considered the first application for a “biosimilar” medication. In this guest post, he describes patients’ role in the drug approval process and how the committee’s decision could influence cancer care in the future.